GLP-1 drugs show cancer promise as oral pill and muscle protector expand the therapeutic landscape

The most striking development in metabolic medicine this month is mounting evidence that GLP-1 receptor agonists, already reshaping obesity and diabetes care, appear to confer protection against cancer. At the American Society of Clinical Oncology meeting in June, researchers presented four correlative studies suggesting the drugs not only reverse the carcinogenic risks associated with obesity but may exert additional anti-inflammatory effects that suppress tumour growth. Viewed from Washington, the signal is treated with cautious optimism: the data remain observational, yet the consistency across cohorts is compelling enough to launch dedicated prospective trials.

On the pharmaceutical front, AstraZeneca’s oral candidate elecoglipron has delivered promising phase 2 results published in The Lancet. The once-daily pill helped adults without diabetes lose up to 10.5 percent of body weight over 26 weeks, with glycaemic improvements mirroring those of injectable GLP-1s. Analysts in London note that an effective oral option could ease the logistical burden of injections and expand access, though nausea remains the most common side effect. Meanwhile, a study in Nature Medicine addresses a troubling consequence of rapid weight loss: the erosion of lean muscle mass, colloquially dubbed “Ozempic butt”. The investigational drug apitegromab, when added to GLP-1 therapy, preserved significantly more muscle without compromising fat loss, Brazilian reports highlight.

Pregnancy and cost concerns are reshaping the risk-benefit calculus. An analysis of more than 3,500 pregnancies published in Annals of Internal Medicine found no significant increase in fetal loss or malformations after early exposure to GLP-1 drugs, though Argentine and Spanish endocrinologists stress that current medical recommendations remain unchanged and the medicines are intended for metabolic disease, not cosmetic use. The affordability picture is darker. A survey of US benefits executives reveals that 49 percent of health plans that do not currently cover GLP-1s for obesity would not do so at any price, and nine in ten respondents are moderately or very concerned about the financial strain on plan budgets.

Two unrelated studies add texture to the broader research landscape. A US trial published in JAMA tracked physical activity in 470 pregnant women and found that those who sat for ten or more hours a day faced higher rates of hypertension, gestational diabetes, and preterm birth—challenging the ingrained belief that rest should dominate pregnancy. Separately, Italian researchers demonstrated that a 36-hour fast before chemotherapy and 24 hours after improved outcomes in advanced ovarian cancer, delaying disease progression by 38 months compared with 24 months in the control group. Arab media reports note the findings add to a growing interest in metabolic interventions beyond pharmaceuticals.

Forward-looking, the GLP-1 class is evolving into a multi-purpose metabolic tool, with oral formulations and muscle-sparing agents poised to address current shortcomings. Yet the tension between clinical promise and payer resistance, particularly in the United States, will determine how broadly these innovations reach patients. If the cancer-protective signal is confirmed in randomised trials, the drugs could be reclassified as preventive agents, further complicating the cost debate. For now, researchers from Rome to Rio de Janeiro are racing to decode the mechanisms, while health systems brace for the financial reckoning that widespread adoption would entail.